CASI Pharmaceuticals, Inc. · OTC:CASIF

CASI Pharmaceuticals — Investor Presentation (September 2021)

21 slides from CASI Pharmaceuticals's investor presentation, September 2021

  1. Slide 1: Partnering Presentation

    Partnering Presentation September 2021

  2. Slide 2: Disclaimer

    Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance, strategies, expectations and goals. Forward-looking statements are subject to

  3. Slide 3: Partnering with CASI – Value Proposition

    Partnering with CASI – Value Proposition A strategic partner for developing and commercializing innovative products in China, the US and Globally • Leverage CASI Pharmaceutical’s expertise and resources in China to accelerate development and commercialization of innovative products into the China ma

  4. Slide 4: CASI - Highlights

    CASI - Highlights • EVOMELA ® - Launched first product in China for Multiple Myeloma in 2019 • Strong growth in sales, with 2020 full-year revenue of $15 million and projected >80% growth in 2021 • CNCT19: CD19 CAR-T Cell Therapy Granted Breakthrough Therapy Designation and on track for 4Q2021 China

  5. Slide 5: China Market Opportunity

    China Market Opportunity • In China, therapeutic oncology treatments grew by 23.6% to $6.3 billion in 2018 and spending has more than doubled since 2013 • New medicines launched since 2013 generated $218 million in spending in 2018 • Drugs are increasingly reaching the market faster in China as a re

  6. Slide 6: Clinical Assets

    Clinical Assets U.S. FDA-Approved Products In-Licensed for Greater China Region In-Licensed CTA Filing & Review Phase 2 Registration NDA Filing & Indication Trial Review EVOMELA Multiple Myeloma Licensed and Commercially Available in China China Developed Innovative Cell Therapy with Co-Commercializ

  7. Slide 7: EVOMELA® Launched in China for Multiple Myeloma

    EVOMELA® Launched in China for Multiple Myeloma Launched in mid-August 2019 – $15 million revenue for 2020, with full-year 2021 revenue guidance of more than 80% growth over 2020 Only form of injectable melphalan commercially available in China Used in preparative regimen for autologous stem cell tr

  8. Slide 8: CNCT-19: CD19 CAR-T Cell Therapy – A Validated Target

    CNCT-19: CD19 CAR-T Cell Therapy – A Validated Target • Targets CD19, a B-cell surface protein widely expressed during all phases of B-cell development and validated target for B-cell derived hematological malignancies • Demonstrated high antitumor efficacy in children and adults with relapsed B-cel

  9. Slide 9: BI-1206: The First Checkpoint Inhibitor Directed Towards Monoclonal Antibody Receptor Interaction

    BI-1206 : The First Checkpoint Inhibitor Directed Towards Monoclonal Antibody Receptor Interaction • BI-1206 is a first-in-class fully human monoclonal antibody that targets FcγRIIB - the only inhibitory Fcγ receptor that acts as a checkpoint or "brake" on the innate immune system • BI-1206 acts lik

  10. Slide 10: CID-103: Fully human IgG1 anti-CD38 monoclonal antibody

    CID-103: Fully human IgG1 anti-CD38 monoclonal antibody with potential Best-in-Class Profile Exclusive global rights Phase 1 trial target initiated in Q1 2021 Fully human IgG1 anti-CD38 mAb recognizing a unique epitope No overt infusion related reactions observed Encouraging preclinical efficacy & s

  11. Slide 11: CB-5339 - Clinical Stage Asset Inhibiting Novel Target VCP/p97

    CB-5339 - Clinical Stage Asset Inhibiting Novel Target VCP/p97 Novel target - VCP/p97 Lead Product - CB-5339 • VCP is a AAA ATPase enzyme that • A 2nd generation small molecule inhibitor of VCP/p97 extracts and unfolds proteins, with biochemical potency of 9 nM essential for cancer cell survival • A

  12. Slide 12: Other Assets

    Other Assets Thiotepa • Exclusive China rights • Conditioning treatment for allogeneic haemopoietic stem cell transplants (EMA) • China registration study initiated in 2021 Octreotide Long Acting Injectable (LAI) • Exclusive China rights • Octreotide LAI formulations considered a standard of care fo

  13. Slide 13: Global Senior Management Team

    Global Senior Management Team Wei-Wu He, PhD Larry Zhang, Chairman and CEO President Jim Goldschmidt, PhD, Alex Zukiwski, MD, SVP, Business Chief Medical Officer Development 13

  14. Slide 14: CASI China Management Team

    CASI China Management Team Thomas Zhang, Junping Chen, PhD Cissy Wang, China Commercial GM Medical Director (CASI COO (CASI China) (CASI China) China) Jonathan You, Michael Wu GM of R&D and Mfg. Regulatory Director Site (CASI WUXI) (CASI China) 14

  15. Slide 15: Commercial Team with Hematologic Oncology Specialty and Track Record

    Commercial Team with Hematologic Oncology Specialty and Track Record • Senior commercial team (VPs, Dirs, DSMs), all with more than 10 years experiences at large international Heilongjiang pharmaceutical companies Jilin IM Liaoning • 90% of employees in commercial BJ Xinjiang operations have prior e

  16. Slide 16: R&D and Manufacturing Center in Wuxi

    R&D and Manufacturing Center in Wuxi • State-of-art GMP facility currently in design and planning stage • Approximately 17.6 acres of land located in major biotech and pharmaceutical region • Over 100,000 square meters of building area • Convenient transportation to 2 airports, high speed train stat

  17. Slide 17: Business Development – Senior Team

    Business Development – Senior Team James E. Goldschmidt, Ph.D. SVP Business Development More than 25 years of senior commercial and business development experience at several public and private biopharmaceutical companies, including GSK, Wyeth/Pfizer, J&J, TetraLogic Pharmaceuticals, Macrophage Ther

  18. Slide 18: Business Development Partners

    Business Development Partners • BioInvent International AB • License agreement for exclusive China rights for first-in-class anti-FcyRIIB monoclonal antibody (BI- 1206) • Black Belt Therapeutics • License agreement for exclusive worldwide rights to a novel anti-CD38 monoclonal antibody (CID- 103) •

  19. Slide 19: CASI – Focused in Hematological Malignancies and Solid Tumors

    CASI – Focused in Hematological Malignancies and Solid Tumors • EVOMELA® (melphalan) for injection launched for Multiple Myeloma in 2019; Hem-Onc sales force have quickly penetrated and expanded the China HSCT market • Robust pipeline in hematology-oncology • CNCT-19 (CD19 CAR-T Cell Therapy) for re

  20. Slide 20: CASI Corporate Offices

    CASI Corporate Offices • CASI Pharmaceuticals, Inc. • CASI Pharmaceuticals (China) (NASDAQ: CASI) Co., Ltd.  9620 Medical Center Drive, Suite  1701-1703 Tower 1,China Central 300; Rockville, MD 20850 Place, No. 81 Jianguo Street, USA Chaoyang district, Beijing, 100025, China 20

  21. Slide 21: Slide 21

CASI Pharmaceuticals — Investor Presentation (September 2021) on 6ix